These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels. Yalçin K, Değertekin H, Kokoğlu OF, Ayaz C. Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116 [Abstract] [Full Text] [Related]
9. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Hepatology; 1991 Apr; 13(4):627-31. PubMed ID: 2010157 [Abstract] [Full Text] [Related]
10. High rate of mutations in the hepatitis B core gene during the immune clearance phase of chronic hepatitis B virus infection. Bozkaya H, Ayola B, Lok AS. Hepatology; 1996 Jul; 24(1):32-7. PubMed ID: 8707278 [Abstract] [Full Text] [Related]
11. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN, Asia Hepatitis Lamivudine Study Group. Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543 [Abstract] [Full Text] [Related]
12. Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients. Kumar M, Chauhan R, Gupta N, Hissar S, Sakhuja P, Sarin SK. Gastroenterology; 2009 Apr; 136(4):1272-80. PubMed ID: 19208347 [Abstract] [Full Text] [Related]